Triumph Program Retatrutide: Inside Eli Lilly's TRIUMPH Clinical Trials

The TRIUMPH program is Eli Lilly's Phase 3 clinical research program for retatrutide, an investigational triple-agonist injection studied for obesity, type 2 diabetes, and several weight-related conditions. Retatrutide is not FDA-approved for any indication, so TRIUMPH trials are currently the only legitimate way to receive the drug. People searching for a "triumph program retatrutide" prescription are really looking at research enrollment, not a pharmacy purchase.

What the TRIUMPH Program Actually Is

TRIUMPH is the umbrella name Eli Lilly uses for its late-stage retatrutide studies. The program bundles multiple separate trials under one label, and each trial targets a different patient population and a different set of health outcomes.

• Randomized and blinded: participants are assigned by chance to retatrutide or placebo, and most trials are double-blind, meaning neither the participant nor the study team knows the assignment.
• Sponsor-funded: Lilly covers the drug, study visits, and study-related care, so participants generally do not pay for the medication itself.
• Regulatory purpose: the data are designed to support a future FDA new drug application.
• Multi-site: trials run at hospitals, academic centers, and dedicated research clinics in the United States and other countries.

Phase 3 is the final stage before a company files for approval, which is why TRIUMPH results carry so much weight. The program follows a Phase 2 study published in the New England Journal of Medicine in 2023, in which participants on the highest dose lost an average of roughly 24% of their body weight over 48 weeks.

How Retatrutide Works: A Triple Agonist, Not a GLP-3

Retatrutide is a single peptide that activates three receptors at once: GLP-1, GIP, and glucagon. Semaglutide targets GLP-1 alone, and tirzepatide targets GLP-1 and GIP.

That third receptor is the key difference. Glucagon agonism is being studied for its effects on energy expenditure and liver fat, which may help explain why weight loss in early retatrutide research exceeded what GLP-1-only drugs typically produce.

One frequently asked question is is retatrutide a glp-3; the accurate answer is no, because no GLP-3 receptor has been identified. Retatrutide is a triple agonist, and people comparing next-generation options often look up cagrilintide vs retatrutide vs tirzepatide to see how the mechanisms differ.

TRIUMPH Trials at a Glance

The registered trials share a similar design but focus on different populations and endpoints. The table below summarizes the general focus of each study.

Trial	Main population	What researchers measure
TRIUMPH-1	Adults with obesity or overweight plus at least one weight-related condition	Percent change in body weight
TRIUMPH-2	Adults with type 2 diabetes and excess weight	Blood sugar (A1c) and weight change
TRIUMPH-3	Adults with obesity and cardiovascular disease	Weight change plus cardiovascular measures
TRIUMPH-4	Adults with obesity and knee osteoarthritis	Weight change and knee pain or function scores
TRIUMPH-5	Adults with obesity and obstructive sleep apnea	Weight change and apnea-hypopnea index
TRIUMPH-Outcomes	Adults with obesity and higher cardiovascular risk	Major cardiovascular events over the long term

Trial titles, enrollment targets, and eligibility rules are updated as studies evolve. Confirm current details on ClinicalTrials.gov before contacting a research site.

Dosing, Injections, and How Long Retatrutide Takes to Work

Retatrutide is given as a once-weekly subcutaneous injection, usually into the abdomen, thigh, or upper arm. Trial doses start low and increase every few weeks — a process called titration — to limit gastrointestinal side effects. The highest dose arms in the program reach 12 mg per week.

When people ask how long does retatrutide take to work, the trial data point to a gradual curve rather than a fast result. Appetite changes often appear within the first few weeks, measurable weight loss builds over roughly 8 to 12 weeks, and most of the total effect is visible by 48 weeks of treatment.

Inside the TRIUMPH program, injections are either administered at clinic visits or taught by the study team, so practical questions like retatrutide how to inject are answered directly by research staff. Self-injection technique is part of the training for participants who dose at home between visits.

Side Effects and Safety Considerations

The most commonly reported side effects in retatrutide research are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually mild to moderate and most frequent during dose increases.

• Heart rate increases have been observed in trials and are monitored at study visits.
• Skin sensations such as tingling or numbness were reported in Phase 2 and continue to be tracked in Phase 3.
• Loss of lean muscle mass is a concern with any rapid weight loss drug, and protocols often include nutrition and resistance-training guidance.
• Like other incretin-based medicines, retatrutide carries theoretical risks related to pancreatitis and gallbladder disease.

Anyone with a history of pancreatitis, gallbladder problems, gastroparesis, or certain thyroid conditions should discuss eligibility with a physician. Only a qualified healthcare professional can determine whether a clinical trial is appropriate for a specific person, and no investigational drug is risk-free.

Approval Status, Brand Name, and How to Join

Retatrutide has no approved brand name in the United States or anywhere else. The retatrutide brand name will only be announced by Eli Lilly if regulators approve the drug, and approval is never guaranteed.

For that reason, any website selling "retatrutide" as a research chemical or a weight loss injection is not selling an FDA-approved product. Unapproved peptides bought online may be mislabeled, contaminated, or dosed incorrectly, and compounded retatrutide has been flagged by regulators as not legally permitted.

Eligibility varies by study, but most TRIUMPH trials require a body mass index in the obesity range, sometimes along with a related condition such as type 2 diabetes, sleep apnea, or knee osteoarthritis. Common exclusions include recent weight loss surgery, use of certain diabetes medications, pregnancy, and a history of severe gastrointestinal disease.

To explore enrollment:

1. Search ClinicalTrials.gov for retatrutide and filter by location and recruiting status.
2. Contact the study site to complete a short phone screening.
3. Attend an in-person visit for labs, a physical exam, and informed consent.
4. Finish any run-in period and randomization steps if you qualify.

Enrollment is voluntary, and participants can withdraw at any time. Travel costs and time commitments are real considerations, and some sites offer stipends for study visits.

COMMON QUESTIONS

Frequently Asked Questions

Is retatrutide available through the TRIUMPH program right now?

Yes, but only to people who qualify and enroll in an active clinical trial. Retatrutide is investigational and is not sold by pharmacies in the United States. You can check ClinicalTrials.gov for recruiting TRIUMPH sites near you and contact them directly.

How much weight do people lose on retatrutide?

In the Phase 2 trial published in 2023, participants on the highest dose lost an average of about 24% of their body weight at 48 weeks. Phase 3 TRIUMPH results are still being reported, so final numbers may differ. Individual results vary widely based on dose, adherence, and baseline health.

Can a doctor prescribe retatrutide like semaglutide or tirzepatide?

No. Retatrutide is not FDA-approved, so it cannot be lawfully prescribed or compounded in the United States. Compounded and online-sold retatrutide products have been flagged by regulators, and their content and sterility are not guaranteed. Ask a healthcare professional about approved options instead.